Last reviewed · How we verify
Original Zoledronic Acid
Original Zoledronic Acid is a Small molecule drug developed by Cttq. It is currently FDA-approved. Also known as: Aclasta.
At a glance
| Generic name | Original Zoledronic Acid |
|---|---|
| Also known as | Aclasta |
| Sponsor | Cttq |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Original Zoledronic Acid CI brief — competitive landscape report
- Original Zoledronic Acid updates RSS · CI watch RSS
- Cttq portfolio CI
Frequently asked questions about Original Zoledronic Acid
What is Original Zoledronic Acid?
Original Zoledronic Acid is a Small molecule drug developed by Cttq.
Who makes Original Zoledronic Acid?
Original Zoledronic Acid is developed and marketed by Cttq (see full Cttq pipeline at /company/cttq).
Is Original Zoledronic Acid also known as anything else?
Original Zoledronic Acid is also known as Aclasta.
What development phase is Original Zoledronic Acid in?
Original Zoledronic Acid is FDA-approved (marketed).
Related
- Manufacturer: Cttq — full pipeline
- Also known as: Aclasta
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing